Abstract
The aim of this study was to assess the expression of BCL11A and MDR1 in AML patients, and its relation to clinical outcome. We grouped the 142patients by the levels of BCL11A and MDR1 and identified three different subgroups: high BCL11A and high MDR1 (n=47), low BCL11A and low MDR1 (n=47) and high BCL11A alone or high MDR1 alone (n=48). The results showed that AML patients with high BCL11A and MDR1 expression had the lowest complete remission and highest relapse rate. The median overall survival of the high BCL11A and high MDR1 group was the shortest among the three groups. With regards to overall survival, there were also significant differences among the groups (p<0.001). High BCL11A and MDR1 expression was associated with a poor response to chemotherapy, and identified a subset of AML patients with a very poor prognosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
